The Janssen Pharmaceutical Companies of Johnson & Johnson announced on Aug. 9, 2019, that FDA granted accelerated approval for Sirturo (bedaquiline) tablets as part of combination therapy in pediatric patients with pulmonary multidrug-resistant tuberculosis (MDR-TB). The drug is indicated foOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.